Brilliant Violet 785™ anti-human CX3CR1
Description
CX3CR1 is a G-protein-coupled seven-transmembrane chemokine receptor, also called GPR13 or V28. It is expressed on NK cells, T cell subset, monocytes/macrophages, dendritic cells, and some malignant epithelial cells. CX3CL1 (known also as fractalkine and neurotactin) is the ligand of CX3CR1. CX3CL1 is a unique transmembrane molecule with a CX3C-motif chemokine domain and a mucin-like stalk. CX3CL1 is expressed by activated-endothelial cells, neurons, and astrocytes. The interaction of CX3CR1 and its ligand mediatesfirm cell adhesion and migration.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.
This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
References
- Nishimura M, et al. 2002. J. Immunol. 168:6173.
- Nanki T, et al. 2002. Arthritis Rheum. 46:2878.
- Kobayashi T, et al. 2007. Inflamm. Bowel Dis. 13:837.
- Beziat V, et al. 2011. J. Immunol. 186:6753. PubMed.